Inovio Pharmaceuticals, Inc. (INO) Presents at The Citizens Life Sciences Conference 2026 Transcript

Silvan Turkin

All right. Welcome back to the Citizens Life Science Conference. My name is Silvan Turkin, and I cover precision sciences at Citizens. It’s my pleasure to host Jacqueline Shea, President and CEO of Inovio. Thank you so much.

Jacqueline Shea
CEO, President & Director

Thank you so much, Silvan. It’s a pleasure to be here today, and thanks for having us.

So I’m going to kick off by just giving you a quick overview of Inovio. Those of you who are not familiar with the story. Just a quick normal looking forward-looking statements disclaimer slide that I’ll be making some forward-looking statements during this presentation. So to provide you a quick overview of the company, we’re a clinical stage biotech company. We’re focused on developing and commercializing our DNA medicines to treat and protect people from HPV-related diseases, cancer and infectious diseases.

We submitted our BLA for our lead program, INO-3107, and it’s been accepted for review by FDA under the accelerated approval program. It’s a potential treatment for a rare disease recurrent respiratory papillomatosis or RRP, which is caused by HPV types 6 and 11. We have a PDUFA target date, October 30 this year, and we have orphan drug and breakthrough therapy designations and orphan drug designation in the EU.

We’ve requested a meeting with FDA to discuss some preliminary comments we received in the file acceptance letter related to eligibility for accelerated approval pathway, and we’re not currently planning to seek approval under the traditional pathway. We continue to believe that the accelerated approval program is the best and fastest path to approval for